Question explored with the scientific record
Conversation so far
- 1 do statins work?
- 2 do statins cause or increase risk of diabetes
Answered on this page ↓
do statins cause or increase risk of diabetes
The short version: yes, statins cause a small but real increase in new-onset diabetes, especially at high doses and in people who already have risk factors.
The evidence is consistent across multiple study designs. A 2018 meta-analysis of 236,864 subjects found statin use associated with a 61% higher odds of new-onset diabetes (fixed-effects OR 1.61, 95% CI 1.55-1.68) [3]. A 2020 Medicare study of 89,390 patients aged 65+ found a 26% increased odds after propensity-score matching [23]. The 2024 Korean nationwide cohort showed a clear dose-response: high-intensity atorvastatin (80 mg) produced 7.7% new-onset diabetes versus 5.7% at 10 mg, and high-intensity rosuvastatin (20 mg) hit 8.3% versus 2.8% at 5 mg [1]. The 2010 Lancet meta-analysis of 91,140 trial participants found a smaller but still significant 9% relative increase (OR 1.09, 95% CI 1.02-1.17) [17].
The mechanism is not a mystery. Statins impair pancreatic beta-cell calcium signaling, downregulate GLUT-4, and increase hepatic gluconeogenesis [8]. Lipophilic statins (atorvastatin, simvastatin) are more diabetogenic than hydrophilic ones (pravastatin) [8]. Pitavastatin appears to carry lower risk than atorvastatin or rosuvastatin [4].
The absolute risk matters. For a person with no diabetes risk factors, the absolute increase is about 0.5% over five years [17]. For someone with metabolic syndrome or prediabetes, it is higher. The 2025 Korean study found that incident diabetes during statin therapy did not worsen cardiovascular outcomes [13], but that does not erase the diabetes diagnosis itself, which carries its own long-term burden.
| Statin type | Dose | New-onset diabetes incidence |
|---|---|---|
| Atorvastatin 10 mg | Low | 5.7% [1] |
| Atorvastatin 80 mg | High | 7.7% [1] |
| Rosuvastatin 5 mg | Low | 2.8% [1] |
| Rosuvastatin 20 mg | High | 8.3% [1] |
| Pitavastatin (moderate) | Moderate | 3.0% [4] |
My call: the diabetes risk is real, dose-dependent, and mechanistically plausible. For people with existing heart disease, the cardiovascular benefit likely outweighs it. For healthy people with low baseline risk, the trade-off is much less favorable.
Sources used 32
-
Different diabetogenic effect of statins according to intensity and dose in patients with acute myocardial infarction: a nationwide cohort study
This nationwide cohort study investigates the differential diabetogenic effects of statins based on their intensity and dose in patients with acute myocardial infarction, revealing that high-intensity statin therapy is associated with a higher incidence of new-onset diabetes mel…
DOI: 10.1038/s41598-024-67585-7 -
Assessment of angiotensin receptor blockers for the hypertensive patients with high salt intake estimated with spot urine
This study investigates the relationship between cardiorespiratory fitness and the risk of developing type 2 diabetes mellitus in hypertensive patients undergoing statin therapy, finding that higher fitness levels are associated with a reduced risk of diabetes.
DOI: 10.1016/j.jash.2016.03.076 -
Statins and New-Onset Diabetes in Cardiovascular and Kidney Disease Cohorts: A Meta-Analysis
A meta-analysis of 11 studies (236,864 subjects) found statin use was associated with a small but statistically significant increased risk of new-onset diabetes mellitus (fixed-effects OR 1.61, 95% CI 1.55-1.68; p < 0.001).
DOI: 10.1159/000485196 -
Effect of Pitavastatin Compared with Atorvastatin andRosuvastatin on New-Onset Diabetes Mellitus in PatientsWith Acute Myocardial Infarction
This study investigates the impact of moderate-intensity pitavastatin compared to atorvastatin and rosuvastatin on the incidence of new-onset diabetes mellitus in patients with acute myocardial infarction, finding that pitavastatin is associated with a significantly lower incide…
DOI: 10.1016/j.amjcard.2018.06.017 -
Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus
This study investigates the association of lipoprotein subclasses and a novel lipoprotein insulin resistance (LPIR) score with the incidence of type 2 diabetes mellitus (T2DM) among individuals randomized to receive either rosuvastatin or placebo in the JUPITER trial, revealing …
DOI: 10.1001/jamacardio.2016.0096 -
The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice
A comprehensive review and practical guidance for clinicians on the diabetes risk associated with statin therapy, evaluating the evidence that statins modestly increase type 2 diabetes risk—especially at high doses—and outlining risk stratification, monitoring, and lifestyle mea…
DOI: 10.1016/j.atherosclerosissup.2014.04.001 -
Statins and New-Onset Diabetes Mellitus and Diabetic Complications: A Retrospective Cohort Study of US Healthy Adults
This retrospective cohort study investigates the association between statin use and the incidence of new-onset diabetes, diabetic complications, and overweight/obesity among healthy adults, revealing that statin users have significantly higher odds of these conditions compared t…
DOI: 10.1007/s11606-015-3335-1 -
Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights
This review synthesizes clinical, epidemiological, and mechanistic evidence showing that statin therapy increases the risk of new-onset type 2 diabetes through multifactorial effects on pancreatic beta-cell function, insulin signaling, hepatic glucose production, and microRNA re…
DOI: 10.3390/ijms21134725 -
Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin
This study investigates the incidence and clinical predictors of new-onset type 2 diabetes mellitus (T2DM) in patients treated with atorvastatin across three large randomized clinical trials, revealing that high-dose atorvastatin is associated with a slight increase in diabetes …
DOI: 10.1016/j.jacc.2010.10.047 -
Evaluation of Statins Use in Hemodialysis Patients: A Retrospective Analysis of Clinical and Safety Outcomes
A single-center, retrospective cohort study in Saudi Arabia assessing safety and effectiveness of statin therapy in end-stage renal disease patients on hemodialysis with dyslipidemia, finding modest LDL-C reductions with atorvastatin and rosuvastatin but no significant reduction…
DOI: 10.3390/ph18060911 -
Lipoprotein(a) predicts a new onset of chronic kidney disease in people with Type 2 diabetes mellitus
Elevated lipoprotein(a) independently predicts the development of new-onset CKD in individuals with Type 2 diabetes; the highest tertile confers HR 2.12 (95% CI 1.33-3.36) for incident CKD after multivariable adjustment.
DOI: 10.1111/dme.12862 -
Ectopic Fat, Insulin Resistance, and Nonalcoholic Fatty Liver Disease
NAFLD is an independent cardiometabolic risk factor for cardiovascular disease and type 2 diabetes, with mechanistic links via hepatic lipid intermediates and insulin resistance; observational evidence supports this, though causality remains to be fully established.
DOI: 10.1161/atvbaha.114.303034 -
Cardiovascular outcomes associated with incident diabetes during statin therapy: a nationwide propensity-matched cohort study
Incident diabetes during statin therapy does not worsen cardiovascular outcomes and does not diminish the cardioprotective benefits of statins, based on two nationwide propensity-matched Korean cohorts.
DOI: 10.1186/s12933-025-03003-0 -
Association between cholesterol levels and dementia risk according to the presence of diabetes and statin use: a nationwide cohort study
Population-based, nationwide cohort analyses show that baseline cholesterol levels are differentially associated with dementia risk depending on diabetes status and statin use, with an inverted J-shaped pattern in statin non-users and a positive LDL-C association among statin us…
DOI: 10.1038/s41598-022-24153-1 -
Impact of Statin Therapy on Diabetes Incidence: Implications for Primary Prevention
This review examines the association between statin therapy and the risk of new-onset diabetes, highlighting that while statins may increase diabetes risk, the cardiovascular benefits significantly outweigh this risk, particularly in individuals with pre-existing diabetes risk f…
DOI: 10.1007/s11886-024-02141-3 -
Therapy and clinical trials
This paper discusses the implications of the ACC/AHA Blood Cholesterol Guidelines on statin therapy, highlighting the increased risk of diabetes associated with higher potency statins while emphasizing the importance of dietary modifications in managing cholesterol levels.
DOI: 10.1097/mol.0000000000000116 -
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
This meta-analysis investigates the relationship between statin therapy and the risk of developing diabetes, finding a slight increase in diabetes risk associated with statin use, particularly in older populations, while emphasizing that the cardiovascular benefits of statins ou…
DOI: 10.1016/s0140-6736(09)61965-6 -
The prevalence and factors associated with aspirin resistance in patients premedicated with aspirin
This study investigates the prevalence and factors associated with aspirin resistance among Jordanian patients, finding that 18.7% of patients are resistant, with significant associations to female gender and diabetes, while statin use improves aspirin response.
DOI: 10.1080/ac.67.4.2170686 -
Association between Statin Use and Sensorineural Hearing Loss in Type 2 Diabetic Patients: A Hospital-Based Study
This study investigates the association between statin use and the risk of sensorineural hearing loss (SNHL) or tinnitus in type 2 diabetic patients, finding that statin use significantly reduces the risk of these conditions.
DOI: 10.3390/ph14111076 -
Relation of Exercise Capacity to Risk of Development of Diabetes in Patients on Statin Therapy (the Henry Ford Exercise Testing Project)
This study investigates the relationship between exercise capacity and the risk of developing diabetes in patients undergoing statin therapy, finding that higher exercise capacity is associated with a lower risk of incident diabetes regardless of statin use.
DOI: 10.1016/j.amjcard.2017.05.048 -
Statins for primary prevention in physically active individuals: Do the risks outweigh the benefits?
This study investigates the association between statin use and cardiovascular outcomes as well as adverse events, particularly diabetes, in physically active military personnel, finding that statin use is linked to increased diabetes risk without significant cardiovascular benef…
DOI: 10.1016/j.jsams.2016.12.075 -
Adverse effects of statin therapy: real evidence
Statins confer clear cardiovascular benefits with generally favorable tolerability; adverse events are typically mild and dose-dependent, while concerns about diabetes, liver function, and cognition are not strongly supported by evidence, and nocebo/drucebo effects contribute to…
DOI: 10.26442/22217185.2019.1.190264 -
Statins are associated with new onset type 2 diabetes mellitus (T2DM) in Medicare patients ≥65 years
This retrospective cohort study of 89,390 Medicare Advantage patients aged ≥65 years found that statin use was associated with new onset type 2 diabetes, with a matched propensity score analysis yielding an odds ratio of 1.26 (95% CI: 1.12–1.41).
DOI: 10.1002/dmrr.3310 -
Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another?
This study investigates the independent associations of metformin, statins, and aspirin with overall mortality among colorectal cancer patients with diabetes, revealing that while statin use is associated with lower mortality, metformin and aspirin do not show such associations …
DOI: 10.1038/bjc.2015.259 -
Lipoprotein-mediated regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and cholesteryl ester metabolism in the adrenal gland of the rat.
Adrenal HMG-CoA reductase activity and cholesteryl ester content in the rat are controlled by the availability of plasma lipoprotein cholesterol; depletion of plasma cholesterol upregulates reductase and depletes esters, which is reversed by lipoprotein cholesterol infusion and …
DOI: 10.1016/s0021-9258(17)40617-x -
Essentiality, Expression, and Characterization of the Class II 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase of Staphylococcus aureus
This study demonstrates that the mvaA gene encoding a class II HMG-CoA reductase is essential for in vitro growth of Staphylococcus aureus, characterizes the enzyme's dual NADP(H)/NAD(H) coenzyme specificity and kinetics, and shows attenuation of virulence when mvaA function is …
DOI: 10.1128/JB.182.18.5147-5152.2000 -
FACTORS SECRETED BY TUMOR-TRANSFORMED FIBROBLASTS ELEVATE THE ACTIVITY OF HMG COA REDUCTASE - CORRELATION TO THE STIMULATIVE EFFECT ON DNA-SYNTHESIS
Factors secreted by virus-transformed fibroblasts elevate HMG CoA reductase activity and DNA synthesis in normal cells, and partially counteract mevinolin-induced growth inhibition, suggesting two mevalonate-dependent growth mechanisms.
DOI: 10.3892/ijo.3.2.361 -
Repurposing statins for the treatment of larval cestodiases: in silico evaluation of statin-HMG-CoA reductase interactions and assessment of statin effects on a cestode model
The study combines in silico analyses and in vitro experiments to evaluate repurposing statins (simvastatin and fluvastatin) as antiparasitic agents targeting HMG-CoA reductase in cestodes, demonstrating that simvastatin markedly reduces viability and motility of Mesocestoides c…
DOI: 10.1017/s0031182024001586 -
Modulation of hypercholesterolemia-induced alterations in apolipoprotein B and HMG-CoA reductase expression by selenium supplementation
This study investigates the effects of selenium supplementation on hypercholesterolemia-induced changes in apolipoprotein B and HMG-CoA reductase expression in male Sprague-Dawley rats, demonstrating that 1 ppm selenium supplementation significantly reduces both apoB levels and …
DOI: 10.1016/j.cbi.2006.02.008 -
Selective Compensatory Induction of Hepatic HMG-CoA Reductase in Response to Inhibition of Cholesterol Absorption
This study investigates the effects of the cholesterol absorption inhibitor ezetimibe on serum cholesterol levels and hepatic HMG-CoA reductase expression in diabetic and thyroidectomized rats, revealing a significant reduction in cholesterol levels and a compensatory increase i…
DOI: 10.1177/153537020623100510 -
Regulation of hepatic cholesterol biosynthesis. Effects of a cytochrome P -450 inhibitor on the formation and metabolism of oxygenated sterol products of lanosterol
Ketoconazole inhibits hepatic cholesterol synthesis by specifically suppressing lanosterol 14a-demethylase, causing accumulation of the C-32 aldehyde and decreased HMG-CoA reductase activity; the aldehyde accumulation is biphasic in liver fractions but linear in hepatocyte cultu…
DOI: 10.1042/bj2640495 -
Brain Cholesterol Synthesis in Mice Is Affected by High Dose of Simvastatin but Not of Pravastatin
High-dose, short-term simvastatin crosses the blood-brain barrier in mice and reduces brain cholesterol synthesis (lower lathosterol and higher HMG-CoA reductase mRNA), while pravastatin does not, with brain cholesterol turnover remaining unchanged.
DOI: 10.1124/jpet.105.094136